Last reviewed · How we verify
dmLT
At a glance
| Generic name | dmLT |
|---|---|
| Also known as | double mutant heat labile toxin, LT(R192G/L211A), LT(R192G/L211A) |
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (PHASE2)
- Phase I Study of ETEC Vaccine (PHASE1)
- A Phase 2 Bridging Study to Assess the New Formulation of ETVAX (PHASE2)
- A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area (PHASE1)
- A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya (PHASE1)
- InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia (PHASE1)
- Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT (PHASE1)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dmLT CI brief — competitive landscape report
- dmLT updates RSS · CI watch RSS
- PATH portfolio CI